Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...

Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday’s episode of her podcast, “Pod Meets World,” that she is being treated for ductal carcinoma in situ. “It is ...

Sensome, the pioneer of microsensing technology for real-time, intra-operative tissue analysis, announced today it has completed enrollment in the first-in-human INSPECT study of its novel technology, ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

This new article publication from Acta Pharmaceutica Sinica B, discusses the use of in situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how molecular glue triggers degradation of PHGDH by enhancing the interaction between DDB1 and PHGDH. Cancer stem cells (CSCs) ...

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable ...